サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1429441

G-CSF（顆粒球コロニー刺激因子）の世界市場レポート 2024

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
G-CSF（顆粒球コロニー刺激因子）の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

G-CSF（顆粒球コロニー刺激因子）の市場規模は、今後数年間で着実に成長すると予想されています。 2028年には4.6%の年間複合成長率（CAGR）で109億8,000万米ドルに成長すると予想されます。予測期間で予想される成長は、がん有病率の増加、顆粒球コロニー刺激因子（G-CSF）の予防需要の高まり、ヘルスケア費の高騰、新興国の潜在力の高さ、技術の進歩、およびバイオシミラー医薬品の普及。予測期間中に予想される注目すべき動向には、効果的で革新的な医薬品の創出を促進するための研究開発活動への多額の投資、顧客基盤と地理的市場を拡大するための合併・買収の成長戦略への一層の焦点、大手企業との戦略的パートナーシップの確立などが含まれます。各プレーヤーは、新薬開発のための研究開発活動を拡大し、収益と製品提供を強化するために好中球減少症治療のためのバイオシミラーの生産に向けた共同の取り組みを拡大します。

G-CSF（顆粒球コロニー刺激因子）市場の成長は、がんの有病率の増加に大きく影響されます。がんは世界の死亡原因の第2位にランクされており、世界中で約6人に1人の死亡を占めています。たとえば、2023年 1月の米国がん協会のデータによると、2023年には米国で新たにがん症例が1,958,310人、がん関連死亡者数が609,820人と予測されています。成長因子のカテゴリーであるG-CSFは重要な役割を果たしています。骨髄内で白血球を生成する役割を果たし、それによって感染症や敗血症のリスクを軽減します。がん患者において、G-CSFは回復を促進し、がん化学療法後の好中球減少症に伴う死亡率を低下させるのに役立ちます。さらに、特定のがん治療後の感染症を軽減する可能性もあります。したがって、がんの有病率の増加は、G-CSF市場の拡大の原動力となる見込みです。

予想されるヘルスケアの増加は、G-CSF市場の将来の成長の触媒として機能すると予想されます。ヘルスケア支出には、医療機器、医薬品、病院ケア、医師サービス、公衆衛生への取り組みなど、さまざまなヘルスケア要素に対する財政支出が含まれます。ヘルスケア支出のレベルはG-CSF市場に重大な影響を及ぼし、G-CSF製品に関連する費用対効果、導入率、コスト削減、市場の成長、予算上の考慮事項などの側面に影響を与えます。メディケア・メディケイド・サービスセンターの2021年から2030年の国民医療支出（NHE）報告書で証明されているように、年間国民医療支出は2021年から2030年の間に平均5.1%増加し、2030年までに推定6兆8,000億米ドルに達すると予測されています。さらに、メディケア支出は年率7.2%で増加すると予想され、メディケイド支出は同期間に年率5.6%で増加すると予測されています。その結果、ヘルスケア支出の増加がG-CSF市場の成長の主要な原動力として浮上しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のG-CSF（顆粒球コロニー刺激因子）市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ペグフィルグラスチム
  • レノグラスチム
  • フィルグラスチム
  • その他のタイプ
  • 世界のG-CSF（顆粒球コロニー刺激因子）市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 錠剤
  • カプセル
  • その他の製品
  • 世界のG-CSF（顆粒球コロニー刺激因子）市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 腫瘍性疾患
  • 血液疾患
  • 慢性および自己免疫疾患
  • その他の用途

第7章 地域および国の分析

  • 世界のG-CSF（顆粒球コロニー刺激因子）市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のG-CSF（顆粒球コロニー刺激因子）市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • G-CSF（顆粒球コロニー刺激因子）市場の競合情勢
  • G-CSF（顆粒球コロニー刺激因子）市場企業プロファイル
    • Amgen Inc.
    • Coherus Biosciences Inc.
    • Sandoz
    • Biocon/Mylan
    • Teva Pharmaceuticals Inc.

第31章 その他の大手および革新的な企業

  • Chugai Pharma
  • Intalfarmaco Group
  • Pfizer
  • Sun Pharmaceutical Industries Limited
  • BeyondSpring Inc.
  • Kyowa Hakko Kirin Co. Ltd
  • BioCad
  • Stada Arzneimittel
  • Dong-A Socio Group
  • Dr. Reddy's Laboratories
  • Celltrion Inc.
  • Emcure Pharmaceuticals
  • Accord Healthcare UK
  • Intas Pharmaceuticals
  • Spectrum Pharmaceuticals

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14453

The G-CSF (granulocyte colony-stimulating factors) market comprises a category of colony-stimulating factors that enhance the bone marrow's capacity to generate more white blood cells. G-CSF is utilized in the treatment of patients with specific tumors, neutropenia resulting from certain chemotherapy types, or severe persistent neutropenia unrelated to cancer treatment. It is also known by other names such as Filgrastim and Granulocyte Colony-Stimulating Factor.

Key types within the G-CSF market include lenograstim, filgrastim, Pegfilgrastim, and others. Lenograstim is a glycosylated recombinant therapeutic drug that closely resembles or is identical to a naturally occurring human granulocyte colony-stimulating factor (G-CSF). The various products are available in forms such as tablets, capsules, and others, and find applications in treating oncological diseases, blood disorders, growth hormone deficiencies, chronic and autoimmune disorders, among others.

The G-CSF (Granulocyte Colony Stimulating Factors) market research report is one of a series of new reports from The Business Research Company that provides G-CSF (Granulocyte Colony Stimulating Factors) market statistics, including G-CSF (Granulocyte Colony Stimulating Factors) industry global market sizes, regional shares, competitors with a G-CSF (Granulocyte Colony Stimulating Factors) market share, detailed G-CSF (Granulocyte Colony Stimulating Factors) market segments, market trends and opportunities, and any further data you may need to thrive in the G-CSF (Granulocyte Colony Stimulating Factors) industry. This G-CSF (granulocyte colony stimulating factors) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The g-csf (granulocyte colony stimulating factors) market size has grown steadily in recent years. It will grow from $8.84 billion in 2023 to $9.17 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth observed in the historical period can be ascribed to an upsurge in cancer prevalence, robust economic expansion in emerging markets, heightened healthcare expenditure, an increase in pharmaceutical research and development expenditure, and government initiatives.

The g-csf (granulocyte colony stimulating factors) market size is expected to see steady growth in the next few years. It will grow to $10.98 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The anticipated growth in the forecast period can be attributed to the increasing prevalence of cancer, a rising demand for prophylaxis granulocyte colony-stimulating factor (G-CSF), an escalation in healthcare expenditure, the high potential of emerging economies, technological advances, and the widespread adoption of biosimilar drugs. Noteworthy trends expected in the forecast period include substantial investments in research and development activities to foster the creation of effective and innovative drugs, a heightened focus on merger and acquisition growth strategies to broaden the customer base and geographic markets, the establishment of strategic partnerships with major players to expand research and development activities for new drug developments, and a concerted effort toward biosimilar production for the treatment of neutropenia to enhance revenues and product offerings.

The growth of the G-CSF (granulocyte colony stimulating factor) market is significantly influenced by the increasing prevalence of cancer. Cancer, ranking as the second leading cause of death globally, accounts for approximately 1 in 6 deaths worldwide. For example, data from the American Cancer Society in January 2023 indicates that an estimated 1,958,310 new cancer cases and 609,820 cancer-related deaths are projected in the United States for the year 2023. G-CSF, a category of growth factors, plays a crucial role in generating white blood cells in the bone marrow, thereby reducing the risk of infection and sepsis. In cancer patients, G-CSF aids in accelerating recovery and decreasing mortality associated with neutropenia following cancer chemotherapy. Moreover, it has the potential to mitigate infections after specific cancer treatments. Consequently, the increasing prevalence of cancer is poised to be a driving force behind the expansion of the G-CSF market.

The anticipated rise in healthcare expenditure is expected to act as a catalyst for the future growth of the G-CSF market. Healthcare expenditure encompasses the financial outlay on various healthcare components, including medical equipment, pharmaceuticals, hospital care, physician services, and public health initiatives. The level of healthcare expenditure holds significant implications for the G-CSF market, influencing aspects such as cost-effectiveness, adoption rates, cost savings, market growth, and budgetary considerations related to G-CSF products. As evidenced by the 2021-2030 National Health Expenditure (NHE) report from the Centers for Medicare & Medicaid Services, annual national health spending is projected to witness an average increase of 5.1% between 2021 and 2030, reaching an estimated $6.8 trillion by 2030. Furthermore, Medicare expenditures are anticipated to grow at a 7.2% annual rate, and Medicaid spending is projected to increase at a 5.6% annual rate during the same period. Consequently, the upswing in healthcare expenditure emerges as a key driver for the growth of the G-CSF market.

Companies in the G-CSF (granulocyte colony stimulating factor) market are strategically emphasizing collaborations to foster innovation and expand their market share. The trend of partnerships, in-licensing, and out-licensing deals has been on the rise, with companies engaging in collaborative ventures with each other, as well as with academic and research institutions. A notable instance from 2022 involves Evive Biotech, a Singapore-based biopharmaceutical company, joining forces with the German pharmaceutical company APOGEPHA. The exclusive long-term license agreement was established for the commercialization of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627, a novel dimeric G-CSF long-acting fusion protein without pegylation, holds promise as a significant product in the market.

Major players in the G-CSF market are actively integrating automation into their product offerings, particularly in the form of automated injection devices, to gain a competitive advantage. Automated injection devices are medical devices designed to deliver a dose of G-CSF automatically into the body at a predetermined time post-chemotherapy. A case in point is Kyowa Kirin Co. Ltd., a Japanese pharmaceutical company, which introduced G-Lasta Subcutaneous Injection 3.6 mg BodyPod in December 2022. This long-acting G-CSF preparation aims to reduce the incidence of febrile neutropenia in patients undergoing cancer chemotherapy. The automated injection device administers a G-Lasta dose approximately 27 hours after connection, eliminating the need for an additional outpatient visit the following day for G-Lasta administration.

In December 2021, when Novartis AG, a Swiss pharmaceutical company, acquired Gyroscope Therapeutics Holdings plc for $800 million. This strategic move is expected to enhance Novartis's portfolio by incorporating G-CSF drugs, bolster gene therapy research capabilities, and bring innovative ophthalmic solutions to treat and prevent blindness on a global scale. Gyroscope Therapeutics Holdings PLC, a UK-based clinical-stage biopharmaceutical company, specializes in the research and development of biosimilars for the treatment of eye-related diseases.

Major companies operating in the g-csf (granulocyte colony stimulating factors) market report are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd., BioCad, Stada Arzneimittel, Dong-A Socio Group, Dr. Reddy's Laboratories, Celltrion Inc., Emcure Pharmaceuticals, Accord Healthcare UK, Intas Pharmaceuticals, Spectrum Pharmaceuticals, Apobiologix, Apotex Inc., Eurofarma Laboratorios, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline PLC, AstraZeneca, Merck Sharp & Dohme Corp., Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Cipla.

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2023. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the g-csf (granulocyte colony stimulating factors) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The G-CSF (granulocyte colony stimulating factors) market consists of sales of releuko, accofil, and pegylated. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on g-csf (granulocyte colony stimulating factors) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for g-csf (granulocyte colony stimulating factors)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The g-csf (granulocyte colony stimulating factors) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Pegfilgrastim; Lenograstim; Filgrastim; Other Types
  • 2) By Product: Tablet; Capsule; Other Products
  • 3) By Application: Oncological Diseases; Blood Disorders; Chronic And Autoimmune Disorders; Other Applications
  • Companies Mentioned: Amgen Inc.; Coherus Biosciences Inc.; Sandoz; Biocon/Mylan; Teva Pharmaceuticals Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. G-CSF (Granulocyte Colony Stimulating Factors) Market Characteristics

3. G-CSF (Granulocyte Colony Stimulating Factors) Market Trends And Strategies

4. G-CSF (Granulocyte Colony Stimulating Factors) Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Size and Growth

  • 5.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global G-CSF (Granulocyte Colony Stimulating Factors) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. G-CSF (Granulocyte Colony Stimulating Factors) Market Segmentation

  • 6.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pegfilgrastim
  • Lenograstim
  • Filgrastim
  • Other Types
  • 6.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Tablet
  • Capsule
  • Other Products
  • 6.3. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oncological Diseases
  • Blood Disorders
  • Chronic And Autoimmune Disorders
  • Other Applications

7. G-CSF (Granulocyte Colony Stimulating Factors) Market Regional And Country Analysis

  • 7.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 8.1. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 9.1. China G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 9.2. China G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 10.1. India G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 11.1. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 11.2. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 12.1. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 13.1. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 14.1. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 14.2. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 15.1. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 15.2. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 16.1. UK G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 17.1. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 18.1. France G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 19.1. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 20.1. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 21.1. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 21.2. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 22.1. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 23.1. North America G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 23.2. North America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 24.1. USA G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 24.2. USA G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 25.1. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 25.2. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 26.1. South America G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 26.2. South America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 27.1. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 28.1. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 28.2. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market

  • 29.1. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market Overview
  • 29.2. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Landscape And Company Profiles

  • 30.1. G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Landscape
  • 30.2. G-CSF (Granulocyte Colony Stimulating Factors) Market Company Profiles
    • 30.2.1. Amgen Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Coherus Biosciences Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Sandoz
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Biocon/Mylan
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Teva Pharmaceuticals Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. G-CSF (Granulocyte Colony Stimulating Factors) Market Other Major And Innovative Companies

  • 31.1. Chugai Pharma
  • 31.2. Intalfarmaco Group
  • 31.3. Pfizer
  • 31.4. Sun Pharmaceutical Industries Limited
  • 31.5. BeyondSpring Inc.
  • 31.6. Kyowa Hakko Kirin Co. Ltd
  • 31.7. BioCad
  • 31.8. Stada Arzneimittel
  • 31.9. Dong-A Socio Group
  • 31.10. Dr. Reddy's Laboratories
  • 31.11. Celltrion Inc.
  • 31.12. Emcure Pharmaceuticals
  • 31.13. Accord Healthcare UK
  • 31.14. Intas Pharmaceuticals
  • 31.15. Spectrum Pharmaceuticals

32. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Benchmarking

33. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The G-CSF (Granulocyte Colony Stimulating Factors) Market

35. G-CSF (Granulocyte Colony Stimulating Factors) Market Future Outlook and Potential Analysis

  • 35.1 G-CSF (Granulocyte Colony Stimulating Factors) Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 G-CSF (Granulocyte Colony Stimulating Factors) Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 G-CSF (Granulocyte Colony Stimulating Factors) Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer